Novel genetic test receives conditional approval from FDA

Signal Genetics, the US-based molecular diagnostic company, has announced that its proprietary gene expression profiling (GEP) based test, Myeloma Prognostic Risk Signature┬« (MyPRS), has received conditional ‘Investigational Drug Exemption’ approval to assist with entry criteria for an upcoming clinical trial. The trial (2012-02 Total Therapy 5B), conducted at the University of Arkansas for Medical Sciences…

Details